) lowered the hemorrha gic activity of the venom alone in CD1 mice by 51.5 ± 2.6 %. Additionally, 1.7 mg extract L -1 plasma prolonged 5.1 times the plasma coagulation time. Fractionation of the extract led to the isolation of two compounds: ononitol (1) and quercetrin (2). The structure of compounds 1 and 2 was esta blished by spectroscopic analyses, including APCIHR MS and NMR ( 1 H, 13 C, HSQC, HMBC and COSY). A quercetrin concentration of 0.11 mmol L -1 prolonged the plasma coagulation time 2.6 times demonstrating that this compound was one of the active constituents of the Brownea rosademonte extract.
than 115 years after the beginning of serotherapy (7), antivenoms remain the only specific treatment for snakebites (8) . Nevertheless, the lack of appropriate antivenom distribution and availability in distant rural places of tropical countries in Africa and Latin America has caused some snakebite victims to seek initial attention from traditional healers in their rural settings before their arrival to the hospital. Thus, they receive extracts of plants in many ways such as drinks, baths, steams and poultices, as reported by Otero et al. (9, 10) in Colombia. Plants could be a potential source for drug discovery in the treatment of neglected tropical diseases like snakebites. A proof is that over 700 plants have been reported in folk medicine for treating snakebites (11) . These plants are an invaluable source for obtaining compounds that could be useful to inhibit some of the toxic effects caused by snakebites. Unfortunately, only a few plants have been evaluated in controlled bioassays and information regarding the isolation of active principles is very limited (11) . Furthermore, the kinetics of the absorption, distribution, metabolism and excretion of plant extracts as well as their concentration in the tissue, are still unknown (12) . Finally, controlled clinical trials in humans, using those plants or their isolated compounds, are not run due to many ethical bans.
In this work, an extract prepared from the leaves of Brownea rosademonte was tested for its neutralizing ability against the hemorrhagic, coagulant, hemolytic and proteolytic effects of B. asper venom from Panama.
EXPERIMENTAL

Animals and venom
CD1 mice (50-70 days) weighing 18 to 19 g were used in the experiments. The animals were provided by the Biotery of the University of Panama (Panama City). The animals were kept in plastic cages under a 12 h light/12 h dark cycle at room temperature (23 ± 2 °C). The animals had free access to food and water. Experiments used the smallest possible number of animals and their suffering was avoided by using sevoflurane as general anesthetic. Animal care and the experimental protocol followed the international guiding principles for biomedical research involving animals.
Mice were divided into four groups of four mice (in duplicate) for use in hemorrhagic experiments as follows: group 1 (control mice treated only with venom), group 2 (mice treated only with plant extract), group 3 (control only with PBS), group 4 (mice treated with venom and plant extract).
The experiments involved the hemorrhagic effect of venom and venom neutralization by the extract. B. asper venom was obtained by milking more than 90 adult specimens of B. asper from four different geographic regions of Panama.
The venom was centrifuged at 3500 x g for 30 min, the supernatant was lyophilized and stored at -40 °C until used. Because of great similarity between B. asper and B. atrox venoms, the minimum inhibitory doses [minimum hemorrhagic dose (MHD), minimum coagulant dose (MCD), minimum indirect hemolytic dose (MIHD) and minimum proteolytic dose (MPD)] for each evaluated effect were determined based on the data previously reported for B. atrox venom (12) (13) (14) (15) . For the experiments, we used the respective reported minimum inhibitory doses plus two high and two low levels of venom (3, 2, 1, 0.5 and 0.3 MIHD). For example, the previously reported MIHD was 0.13 mg L It is important to clarify that experiments carried out to determine the antihemorrhagic effect of B. rosademonte on mice are considered to be in vitro because the crude plant extract was preincubated together with venom before being injected to test mice.
Plant collection and extract preparation
B. rosademonte (Caesalpiniaceae) leaves were collected in the Parque Nacional Alto Chagres Panama; voucher specimens are deposited at the Herbarium of the University of Panama (Panama City, Panama). After sun drying fresh leaves and crushing them in a standard blender to obtain coarse powder, the extract was prepared by maceration with 96 % ethanol for two days. Extract was concentrated to a semisolid paste using a rotary evaporator (Laborota 4010, Germany) to obtain 18.17 g of crude extract (6.2 % of plant yield) and stored at -4 °C until used.
Brine shrimp lethality assay
In vitro lethality assay of Artemia salina extract was used to detect cell toxicity. Brine shrimp eggs were placed in seawater [3.8 %, m/V, TetraMarine sea salt (United Pet Group, Inc., USA) in distilled water] and incubated at 28 °C. Eggs were hatched within 48 h providing a large number of larvae (nauplii). Ten nauplii were placed in each vial containing 5 mL of seawater and increasing concentrations of B. rosademonte extract (10, 50, 100, 500 and 1000 µg mL -1 ). Each concentration was assessed in triplicate. Percentage of lethality was determined by comparing the mean number of surviving larvae of the test and control vials. LC 50 values were obtained from the bestfit line of plotted concentration vs. percentage of lethality. Potassium dichromate was used as a positive control in the bioassay while the negative control contained only the solvent (methanol) used for the preparation of test samples (16) . ) dissolved in 0.1 mL PBS, pH 7.2. Then, the mixture was injected i.d. into four mice (group 4). Two hours later, mice were sacrificed by sevoflurane inhalation, and the diameter of the hemorrhagic area was measured (12) .
Antihemorrhagic activity of the extract
Neutralization of the proteolytic activity of venom
Proteolytic activity of B. asper venom (10-250 µg mL ) of B. asper venom. Casein (2 mL) in PBS pH 7.2 was then added to the mixture and again incubated for 30 min at 37 °C. The reaction was stopped by addition of 5 % trichloroacetic acid. The mixture was centrifuged at 3500xg for 10 min and absorbance of the supernatant was measured at 280 nm, in a Lambda 20 UV/VIS spectrometer (Perkin Elmer, USA). The experiment was repeated three times and results were expressed as mean ± SD.
Neutralization of indirect hemolytic activity of venom
The agaroseerythrocyteegg yolk assay was used (14) . Plant extract (25-1600 µg) was tested against one MIHD (195 ± 7 µg mL ) of venom and the result was expressed as mean ± SD. The experiments were perfomed in duplicate.
Neutralization of coagulant effect of venom
Human plasma was used to assess the coagulant effect. Plasma was donated by the National Blood Bank (Panama City, Panama). The plasma came from healthy donors and complied with the Caja del Seguro Social (CSS, Panama National Hospital) requirements for use in biological experimentation and with permission from the donors. The method described by Theakston and Reid (18) was used with small modifications. Briefly, 1.0 µg of B. asper venom dissolved in 50 µL PBS, pH 7.2, was added to human plasma (0.3 mL), preincubated at 37 °C and the time required for plasma coagulation was determined. To evalu ate the neutralizing capacity of the plant extract against the coagulant effect of venom, one MCD (1.7 µg mL -1 ) of B. asper venom was dissolved in 50 µL PBS, pH 7.2, and preincubated at 37 °C for 30 min with the plant extract (100 or 200 µg) and then, the mixture was added to human plasma (0.3 mL) and preincubated at 37 °C. The time required for plasma coagulation was determined (15) .
Chemical procedures
NMR spectra were acquired on a Jeol Eclipse 400 MHz spectrometer (Jeol, Japan) and referenced to residual solvent: Purification of the compounds was carried out by gel permeation column chromatography using Sephadex LH20 (SigmaAldrich, USA) and column chromatography on silica gel 60 (0.063-0.210 mm, Merck, Germany). TLC (analytical) was performed on precoated silica gel 60 F254 plates (Merck). All solvents were of analytical reagent grade (ACS) grade and were used without further purification.
Extraction and isolation of ononitol and quercetrin from B. rosademonte extract
A portion of crude extract (10 g) was dissolved in a methanol/water mixture (90:10) and partitioned successively with ethyl acetate and hexane. All three fractions were evaporated to dryness using a rotar evaporator at low temperature (30 °C). Water fraction (2.5 g) was fractionated by gel permeation column chromatography using Sephadex LH20 (50 g) and eluted with a methanol/water mixture (90:10, V/V) for three days, giving 36 fractions. A major and active fraction (F4, 800 mg) was fractionated by column chromatography on silica gel 60 (50 g). The column was eluted with hexane, followed by a gradient of hexane/ CHCl 3 (1:0→0:1) and finally with a gradient of CHCl 3 /methanol (1:0→1:1). Altogether, 10 secondary fractions (FI to FX) were obtained. Because of the low yield and high complexity of fractions, we proceeded to work with major fractions only. From major fraction FIII eluted with chloroform/methanol (8:2, V/V), 300 mg of ononitol (0.019 % of plant yield, compound 1) was purified by recrystallization (17) . Fraction FVII (40 mg) was further subjected to silica gel 60 column chromatography and eluted with a gradient of hexane/chloroform (1:0→0:1) and chloroform/methanol (1:0→1:1). This process led to fifteen secondary fractions (F71 to F715). Fraction F79 eluted with 100 % ethyl acetate was filtered and 12.1 mg of quercetrin (0.007 % of plant yield, compound 2) was obtained in the supernatant (18) .
RESULTS AND DISCUSSION
Looking for alternatives to combat snakebites in Panama, we have chosen the leaves of B. rosademonte to evaluate their properties against some B. asper venom toxic effects. This plant is used by traditional healers and in a previous study its stem bark extract showed in vitro neutralizing ability against the lethal, hemorrhagic, edema formating, defibrinating and coagulant effects of B. atrox asper venom (15) .
As a first step, we evaluated the lethality of crude extract against brine shrimp (A. salina larvae) to verify the intrinsic toxicity of B. rosademonte. In the brine shrimp test, the plant extract showed an LC 50 above 1000 µg mL , respectively.
Once the minimum doses were determined, we proceeded to evaluate the effect of the plant against those caused by snake venom and it was found that ethanolic extract from the leaves of B. rosademonte had significant in vitro activity against coagulant and hemorrhagic effects provoked by B. asper venom at 5.5 mg kg -1 b. m. significantly lowered 51.5 ± 2.6 % the hemorrhagic activity of B. asper venom (Fig. 1) and at 1.7 mg extract L -1 plasma prolonged the plasma coagulation time induced by the venom until 5.1 times. This may indicate the possible inhibition of venom metalloproteinases responsible for local and systemic hemorrhage, as well as the thrombinlike enzymes of venom responsible for plasma coagulation by this plant extract. Ethanolic extract significantly prolonged the plasma coagulation time when preincubated with the venom (one microgram of venominduced coagulation of human plasma in 30.1 ± 1.5 s). This effect was dosedependent because 1.7 mg of extract L -1 of plasma showed a coagulation time of 155.3 ± 2.4 s, whereas 3.4 mg of extract L -1 plasma delayed the coagulation time to 350.4 ± 3.9 s (p < 0.001). Proteolytic and indirect hemolytic activities of B. asper venom were not neutralized by the ethanolic extract prepared from the leaves of B. rosademonte.
Chemistry
Steroids, triterpenes, flavonoids and tannins were detected in the plant extract by TLC analysis (21).
Subsequent extract fractionation and compound purification were carried out by se veral chromatographic methods. These processes led isolation of two major components: ononitol (1) and quercetrin (2) from B. rosademonte (Fig. 2) .
Compound 1 was isolated as a colorless crystalline solid. Its molecular formula was determined as C 7 H 15 O 6 by APCIHRMS. The 13 C NMR spectrum for 1 (Table I) suggested the presence of a rhamnose unit in the structure of compound 2. Based on the above evidence, the structure of 2 was defined as quercetrin. The structure of compound 2 was confirmed by comparing our experimental data with those reported by Hanamura et al. (20) .
Compounds 1 and 2 (with approximately 98 % purity level) were tested against the hemorrhagic and coagulant activities of B. asper venom. Only compound 2 showed neutralizing capacity against the coagulant effect of venom. A concentration of 0.11 µmol L -1 of quercetrin prolonged the plasma coagulation time in the presence of 1 µg of venom 2.6 times. Unfortunately, it was not possible to isolate other pure active compounds with the methodology used. However, we found out that highly polar fractions were those that showed the antihemorrhagic effect. This fact shows that highly hydroxylated compounds may be the main antihemorrhagic components of the plant.
CONCLUSIONS
Biological assessments performed with B. rosademonte ethanolic extract allowed us to demonstrate that this plant possesses significant activity in vitro against coagulant and hemorrhagic effects induced by B. asper venom. In the brine shrimp test, the organic extract of B. rosademonte showed no cytotoxicity (LC 50 above 1000 µg mL -1 ). On the other hand, it was demonstrated that quercetrin is one of the major anticoagulant compounds of that plant. To our knowledge, this is the first report on the isolation and structural characterization of some compounds produced by Brownea rosademonte.
